Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 12/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.40 |
| ▸ | SCN1A | P35498 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27875524 | 0.88 | KCNH2 (0.40) | KCNH2SCN10ASCN5ASCN1ASCN9A | |
| SCHEMBL31375506 | 0.87 | KCNH2 (0.36) | KCNH2SCN10ASCN5ASCN1ASCN9A | |
| SCHEMBL9062115 | 0.85 | RXRA (0.48) | KCNH2SCN10ASCN5ASCN1ASCN9A | |
| SCHEMBL9062321 | 0.84 | RXRA (0.47) | KCNH2SCN10ASCN5ASCN1ASCN9A | |
| SCHEMBL508392 | 0.84 | KCNH2 (0.42) | KCNH2SCN10ASCN5ASCN1ASCN9A | |
| SCHEMBL19514109 | 0.84 | SCN10A (0.47) | KCNH2SCN10ASCN5ASCN1ASCN9A | |
| SCHEMBL30430478 | 0.83 | SCN5A (0.43) | KCNH2SCN10ASCN5ASCN1ASCN9A | |
| SCHEMBL508451 | 0.81 | SCN10A (0.47) | KCNH2SCN10ASCN5ASCN1ASCN9A | |
| SCHEMBL5347935 | 0.81 | CHRNA7 (0.47) | KCNH2SCN10ASCN5ASCN1ASCN9A | |
| SCHEMBL9060808 | 0.80 | CHRNA7 (0.46) | KCNH2SCN10ASCN5ASCN1ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9198913-B2 | Nitroimidazooxazines and their uses in anti-tubercular therapy | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2459571-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | Global Alliance For Tb Drug Development (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2011014774-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | NOX5, MT-ND5, NQO1 | KCNH2 3157/4885SCN10A 4460/4885SCN5A 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.